A Study of TAK-861 in Participants With Narcolepsy Type 1
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05687903|
Recruitment Status : Recruiting
First Posted : January 18, 2023
Last Update Posted : March 17, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
The main aim of this study is to see how TAK-861 works on symptoms of narcolepsy, including excessive daytime sleepiness and cataplexy. Approximately 100 participants will take part in the study across North America, Europe and Asia Pacific.
The treatment (TAK-861 or placebo) will be administered for 8 or 12 weeks. After this treatment period the participant will have the option to participate in a separate, long- term extension study during which all participants will be treated with TAK-861.
|Condition or disease||Intervention/treatment||Phase|
|Narcolepsy Type 1||Drug: TAK-861 Drug: Placebo||Phase 2|
The drug being tested in this study is called TAK-861. This study will look at the effect of TAK-861 on improvement in narcolepsy symptoms, including excessive daytime sleepiness (EDS) and number of cataplexy episodes.
The study will enroll approximately 100 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the five treatment groups which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):
- TAK-861 Dose 1
- TAK-861 Dose 2
- TAK-861 Dose 3
- TAK-861 Dose 4
- Placebo (dummy inactive pill) - this is a tablet that looks like the study drug but has no active ingredient
This multi-center trial will be conducted worldwide. The overall time to participate in this study is up to 23 weeks. Participants will make multiple visits to the clinic during the treatment period and then will either enroll in a long-term extension study in which all participants will receive TAK-861 or have 2 final visits 7 and 28 days after last dose of study drug for follow-up assessments.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Care Provider)|
|Official Title:||A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-861 for the Treatment of Narcolepsy With Cataplexy (Narcolepsy Type 1)|
|Actual Study Start Date :||January 9, 2023|
|Estimated Primary Completion Date :||May 29, 2024|
|Estimated Study Completion Date :||May 29, 2024|
Experimental: TAK-861 Dose 1
Participants will receive TAK-861 dose 1, orally, from Day 1 up to Weeks 8 or 12.
Experimental: TAK-861 Dose 2
Participants will receive TAK-861 dose 2, orally, from Day 1 up to Weeks 8 or 12.
Experimental: TAK-861 Dose 3
Participants will receive TAK-861 dose 3, orally, from Day 1 up to Weeks 8 or 12.
Experimental: TAK-861 Dose 4
Participants will receive TAK-861 dose 4, orally, from Day 1 up to Weeks 8 or 12.
Placebo Comparator: Placebo
Participants will receive TAK-861 matching placebo tablets, orally, from Day 1 up to Weeks 8 or 12.
TAK-861 placebo matching tablets
- Change from Baseline to Week 8 in Mean Sleep Latency from the Maintenance of Wakefulness Test (MWT) [ Time Frame: Baseline, Week 8 ]The MWT evaluates a person's ability to remain awake under soporific conditions for a defined period of time. Because there is no biological measure of wakefulness, wakefulness is measured indirectly by the inability or delayed tendency to fall asleep. This tendency to fall asleep is measured via electroencephalography-derived sleep latency in the MWT. The MWT consists of four 40-minute sessions done 2 hours apart. Sleep latency in each session will be recorded. Participants will be required to stay awake in between the 4 sessions.
- Change from Baseline to Week 8 in Epworth Sleepiness Scale (ESS) Total Score [ Time Frame: Baseline, Week 8 ]The ESS provides individuals with 8 different situations of daily life and asks them how likely they are to fall asleep in those situations (scored 0 to 3) and to try to imagine their likelihood of dozing even if they have not actually been in the identical situation; the scores are summed to give an overall score of 0 to 24. Higher scores indicate stronger subjective daytime sleepiness, and scores below 10 are considered to be within the normal range.
- Weekly Cataplexy Rate at Week 8 [ Time Frame: Week 8 ]
- Occurrence of at Least One Related Treatment-emergent Adverse Event (TEAE) [ Time Frame: Baseline up to approximately 16 weeks ]An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product. A TEAE is defined as any event emerging or manifesting at or after the initiation of treatment with a study intervention or medicinal product or any existing event that worsens in either intensity or frequency following exposure to the study intervention or medicinal product.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||16 Years to 70 Years (Child, Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
The participant is aged 18 to 70 years, inclusive, at the time of signing the informed consent form (ICF).
Note: In Japan, participants aged 16 to 70 years, inclusive, may be included.
- The participant has body mass index (BMI) within the range 18 to 40 kilogram per square meter [kg/m^2] (inclusive).
- The participant has an International Classification of Sleep Disorders, 3rd Edition (ICSD-3) diagnosis of narcolepsy type 1 (NT1) by polysomnography (PSG)/Multiple Sleep Latency Test (MSLT), performed within the past 10 years.
- The participant is positive for the human leukocyte antigen (HLA) genotype HLA-DQB1*06:02 or results from cerebrospinal fluid (CSF) testing indicate the participant's CSF orexin (OX)/hypocretin-1 concentration is <110 picograms per milliliter ([pg/mL] (or less than one-third of the mean values obtained in normal participants within the same standardized assay).
- The participant has a current medical disorder, other than narcolepsy with cataplexy, associated with EDS.
- The participant has medically significant hepatic or thyroid disease.
- The participant has a history of cancer in the past 5 years (does not apply to participants with carcinoma in situ that has been resolved without further treatment or basal cell cancer).
- The participant has clinically significant coronary artery disease, a history of myocardial infarction, clinically significant angina, clinically significant cardiac rhythm abnormality, or heart failure.
- The participant has a clinically significant history of head injury or head trauma.
- The participant has history of epilepsy, seizure, or convulsion, or has a family history of inherited disorders associated with seizure (except for a single febrile seizure in childhood).
The participant has one or more of the following psychiatric disorders:
- Any current unstable psychiatric disorder.
- Current or history of manic or hypomanic episode, schizophrenia or any other psychotic disorder, including schizoaffective disorder, major depression with psychotic features, bipolar depression with psychotic features, obsessive compulsive disorder, intellectual disability, organic mental disorders, or mental disorders due to a general medical condition as defined in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5).
- Current diagnosis or history of substance use disorder as defined in the DSM-5.
- Current active major depressive episode (MDE) or who have had an active MDE in the past 6 months.
- The participant has a history of cerebral ischemia, transient ischemic attack (<5 years ago), intracranial aneurysm, or arteriovenous malformation.
- The participant has a positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus (HIV) antibody/antigen.
- The participant's renal creatinine clearance (Cockcroft-Gault Equation) is ≤50 mL/minute.
- The participant has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) values >1.5 times the upper limit of normal (ULN).
- The participant is considered by the investigator to be at imminent risk of suicide or injury to self, others, or property, or the participant has attempted suicide within the past year.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05687903
|Contact: Takeda Contact||+1-877-825-3327||medinfoUS@takeda.com|
|United States, Alabama|
|Sleep Disorders Center of Alabama||Recruiting|
|Birmingham, Alabama, United States, 35213-1966|
|United States, California|
|SDS Clinical Trials, Inc.||Recruiting|
|Santa Ana, California, United States, 92705-8519|
|United States, Colorado|
|Delta Waves LLC - Hunt - PPDS||Recruiting|
|Colorado Springs, Colorado, United States, 80918|
|United States, Florida|
|Florida Pediatric Research Institute||Recruiting|
|Orlando, Florida, United States, 32803-1468|
|United States, Georgia|
|Atlanta, Georgia, United States, 30342-1743|
|Georgia Neuro Center||Recruiting|
|Gainesville, Georgia, United States, 30501-3883|
|United States, Missouri|
|St. Lukes Sleep Medicine and Research Center||Recruiting|
|Chesterfield, Missouri, United States, 63017-3406|
|United States, North Carolina|
|Research Carolina Elite||Recruiting|
|Denver, North Carolina, United States, 28037|
|ARSM Research, LLC||Recruiting|
|Huntersville, North Carolina, United States, 28078-5082|
|United States, Ohio|
|Cincinnati, Ohio, United States, 45227-2172|
|Ohio Sleep Medicine Institute||Recruiting|
|Dublin, Ohio, United States, 43017-3521|
|United States, South Carolina|
|Bogan Sleep Consultants, LLC||Recruiting|
|Columbia, South Carolina, United States, 29201-2923|
|United States, Texas|
|Sleep Therapy and Research Center||Recruiting|
|San Antonio, Texas, United States, 78229-4849|
|United States, Virginia|
|Children's Specialty Group||Recruiting|
|Norfolk, Virginia, United States, 23510-1021|
|Study Director:||Study Director||Takeda|
|Other Study ID Numbers:||
2022-001654-38 ( EudraCT Number )
U1111-1277-4261 ( Other Identifier: WHO )
|First Posted:||January 18, 2023 Key Record Dates|
|Last Update Posted:||March 17, 2023|
|Last Verified:||March 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Yes|
|Plan Description:||Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.|
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
|Access Criteria:||IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
|Product Manufactured in and Exported from the U.S.:||No|
Disorders of Excessive Somnolence
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Nervous System Diseases